Current treatment strategies for inhibiting mTOR in cancer

Francesca Chiarini, Camilla Evangelisti, James A. McCubrey, Alberto M. Martelli

Research output: Contribution to journalArticlepeer-review


Mammalian target of rapamycin (mTOR) is a Ser/Thr kinase that regulates a wide range of functions, including cell growth, proliferation, survival, autophagy, metabolism, and cytoskeletal organization. mTOR activity is dysregulated in several human disorders, including cancer. The crucial role of mTOR in cancer cell biology has stimulated interest in mTOR inhibitors, placing mTOR on the radar of the pharmaceutical industry. Several mTOR inhibitors have already undergone clinical trials for treating tumors, without great success, although mTOR inhibitors are approved for the treatment of some types of cancer, including advanced renal cell carcinoma. However, the role of mTOR inhibitors in cancer treatment continues to evolve as new compounds are continuously being disclosed. Here we review the three classes of mTOR inhibitors currently available for treating cancer patients. Moreover, we highlight efforts to identify markers of resistance and sensitivity to mTOR inhibition that could prove useful in the emerging field of personalized medicine.

Original languageEnglish
Pages (from-to)124-135
Number of pages12
JournalTrends in Pharmacological Sciences
Issue number2
Publication statusPublished - 2015


  • ATP-competitive mTOR inhibitors
  • dual PI3K/mTOR inhibitors
  • rapalogs
  • rapamycin
  • translation

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology


Dive into the research topics of 'Current treatment strategies for inhibiting mTOR in cancer'. Together they form a unique fingerprint.

Cite this